SF 2312: Relating to manufacturers and distributors of 340B drugs

What it does

This bill relates to manufacturers and distributors of 340B drugs. “340B drug”, “manufacturer”, and “distributor” are defined in the bill. The bill prohibits a manufacturer or distributor from, directly or indirectly, denying, restricting, or interfering with the acquisition of a 340B drug by a covered entity, or the delivery of a 340B drug to a contract pharmacy, unless otherwise prohibited by the United States department of health and human services.

Senate subcommittee · named February 18, 2026

• Sen. Annette Sweeney (R) · annette.sweeney@legis.iowa.gov
• Sen. Izaah Knox (D) · izaah.knox@legis.iowa.gov
• Sen. Kara Warme (R) · kara.warme@legis.iowa.gov

Lobbying · 8 for, 10 against

For: Iowa Chapter-American Academy of Pediatrics; Iowa Hospital Association; Iowa Integrated Health Planning and Advisory Council; Iowa Medical Society; Iowa Pharmacy Association; Iowa Primary Care Association; Mindspring Mental Health Alliance; United Way Quad Cities

Against: Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb Co.; Eli Lilly & Co.; GSK; Genentech, Inc., A Member of the Roche Group; Iowa Biotechnology Association; Merck Sharp & Dohme LLC; Novartis Services, Inc.; Novo Nordisk; Pharmaceutical Research and Manufacturers of America (PhRMA)

In plain words

1. February 12, 2026Filed in the Senate and sent to the Commerce committee
2. February 18, 2026Senate subcommittee named: Sweeney, Knox and Warme